Cytosorbents Corporation (NASDAQ: CTSO)
$0.9112
-0.0038 ( +0.13% ) 51.5K
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Market Data
Open
$0.9112
Previous close
$0.9150
Volume
51.5K
Market cap
$50.56M
Day range
$0.8760 - $0.9300
52 week range
$0.7000 - $1.8200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Dec 23, 2024 |
4 | Insider transactions | 1 | Dec 16, 2024 |
4 | Insider transactions | 1 | Dec 13, 2024 |
8-k | 8K-related | 31 | Dec 09, 2024 |
8-k | 8K-related | 15 | Nov 07, 2024 |
10-q | Quarterly Reports | 63 | Nov 07, 2024 |
4 | Insider transactions | 1 | Oct 08, 2024 |
4 | Insider transactions | 1 | Oct 08, 2024 |
8-k | 8K-related | 15 | Oct 01, 2024 |
8-k | 8K-related | 17 | Oct 01, 2024 |